dc.contributor.author |
Kampa-Schittenhelm, Kerstin Maria |
de_DE |
dc.contributor.author |
Akmut, Figen |
de_DE |
dc.contributor.author |
Schittenhelm, Marcus Matthias |
de_DE |
dc.date.accessioned |
2013-12-16T13:12:45Z |
|
dc.date.available |
2013-12-16T13:12:45Z |
|
dc.date.issued |
2013 |
de_DE |
dc.identifier.issn |
1476-4598 |
de_DE |
dc.identifier.uri |
http://hdl.handle.net/10900/39671 |
|
dc.language.iso |
en |
en |
dc.publisher |
Biomed Central Ltd |
de_DE |
dc.relation.uri |
http://dx.doi.org/10.1186/1476-4598-12-19 |
de_DE |
dc.rights |
info:eu-repo/semantics/closedAccess |
|
dc.subject.ddc |
570 |
de_DE |
dc.subject.ddc |
610 |
de_DE |
dc.title |
Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms |
de_DE |
dc.type |
Article |
de_DE |
utue.quellen.id |
20130911224530_01424 |
de_DE |
utue.personen.roh |
Kampa-Schittenhelm, Kerstin Maria |
de_DE |
utue.personen.roh |
Heinrich, Michael Charles |
de_DE |
utue.personen.roh |
Akmut, Figen |
de_DE |
utue.personen.roh |
Doehner, Hartmut |
de_DE |
utue.personen.roh |
Doehner, Konstanze |
de_DE |
utue.personen.roh |
Schittenhelm, Marcus Matthias |
de_DE |
dcterms.isPartOf.ZSTitelID |
Molecular Cancer |
de_DE |
dcterms.isPartOf.ZS-Issue |
Article 19 |
de_DE |
dcterms.isPartOf.ZS-Volume |
12 |
de_DE |
utue.fakultaet |
04 Medizinische Fakultät |
de_DE |